OverviewChartNewsTraderScreen

Bavarian Nordic A/S/  DK0015998017  /

Nasdaq Other OTC
28/05/2024  19:45:07 Chg. +2.3000 Volume Bid- Ask- High Low
24.9900USD +10.14% 650
Turnover: 14,609		 -Bid Size: - -Ask Size: - 24.9900 24.2200
GlobeNewswire 07/05 Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire 29/04 Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chiku...
GlobeNewswire 02/04 Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
GlobeNewswire 20/03 Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire 23/02 Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines...
GlobeNewswire 15/02 Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
GlobeNewswire 09/11/2023 Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
GlobeNewswire 08/11/2023 Emergent BioSolutions Reports Third Quarter 2023 Financial Results
GlobeNewswire 21/09/2023 Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
TeleTrader 19/08/2022 EU makes monkeypox vaccine more available
TeleTrader 18/08/2022 WH announces new strategies against monkeypox
TeleTrader 30/07/2022 Spain confirms second monkeypox death
TeleTrader 29/07/2022 Spain confirms Europe's first monkeypox death
TeleTrader 25/07/2022 Monkeypox vaccine approved by EU
TeleTrader 22/07/2022 EMA gives preliminary approval to monkeypox jab
TeleTrader 14/06/2022 EU buys 110,000 monkeypox vaccines
TeleTrader 27/05/2022 EU to jointly buy antivirals, vaccines against monkeypox
GlobeNewswire 24/03/2022 Valneva Reports Full Year 2021 Results and Provides Corporate Updates
GlobeNewswire 21/03/2022 Bavarian Nordic Announces License and Supply Agreement with Nuance Pharma on the Development and Com...
GlobeNewswire 28/02/2022 Bavarian Nordic Reports Additional Positive Phase 2 Results for its COVID-19 Vaccine Candidate Ahead...
GlobeNewswire 14/02/2022 Bavarian Nordic Announces Breakthrough Therapy Designation for its RSV Vaccine Candidate for the Pre...
GlobeNewswire 03/02/2022 Valneva Reports Full Year 2021 Revenue and Cash; Provides First 2022 Guidance
GlobeNewswire 06/12/2021 Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening it...
GlobeNewswire 05/12/2021 Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate
GlobeNewswire 18/11/2021 Valneva Reports Nine-Month 2021 Revenue and Cash